Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY (DHA)

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-26-Q-9302

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a solicitation (Procurement Identifier: HT9402-26-Q-9302) seeking quotations for participation in the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP). This procurement is mandated by 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21), which require the establishment of an integrated, efficient pharmacy benefits program for the Military Health System (MHS). The program’s primary objective is to ensure the effective acquisition and management of pharmaceutical agents for military beneficiaries. The scope of this solicitation encompasses the provision of pharmaceutical agents within specific drug classes identified for potential inclusion on the DoW Uniform Formulary (UF). The selection process is guided by the Pharmacy and Therapeutics (P&T) Committee, which evaluates the clinical and cost effectiveness of agents in each therapeutic class. The outcomes of this procurement activity are intended to support the selection and classification of pharmaceutical agents as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF), thereby optimizing cost-sharing and access for MHS beneficiaries. For the May 2026 P&T Committee meeting, the following newly approved drugs will be reviewed for potential UF placement: - Lifyorli (Oncological Agents – Glucocorticoid Receptor Antagonist) - Quiofic (Vitamins – Water Soluble) - Widaplik (Antihypertensive Agents) - Saphnelo (Immunosuppressives) Interested pharmaceutical manufacturers are invited to submit quotations in response to the attached Request for Quotation (RFQ), which includes detailed instructions, deadlines, and appendices related to the UF BPA and UF ADP. The procurement is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505, with the primary place of performance in San Antonio, Texas. Key requirements for participation include: - Submission of quotations for pharmaceutical agents within the identified drug classes - Adherence to the clinical and cost evaluation criteria as outlined by the P&T Committee - Compliance with all instructions and deadlines specified in RFQ HT9402-26-Q-9302 - Participation in a pre-quotation teleconference scheduled for May 13, 2026, as detailed in Part 2.4 of the RFQ - Timely response to clinical questions (Part 3.4), to be submitted via email to the designated point of contact The contracting entity for this opportunity is the Defense Health Agency (DHA), a federal office within the Department of Defense. The primary point of contact is Tracy Banks ([email protected]), with secondary contact Kirk Heyen ([email protected], phone: 830.931.766). This solicitation is currently active, with a response deadline of May 28, 2026, at 17:05. All relevant documents, including the RFQ and appendices, are available via the official SAM.gov opportunity posting (Opportunity ID: cc93cf8ed0774bebbc781e5999c79061). Contractors with capabilities in pharmaceutical preparation manufacturing and experience in federal pharmacy benefit programs are encouraged to review the attached RFQ and consider this opportunity. The procurement process is designed to ensure transparency, competitive pricing, and the selection of clinically effective agents for the Military Health System’s Uniform Formulary.
Documents9